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Autosomal dominant polycystic kidney disease (PKD) is a hereditary disorder affecting
multiple organs, including the heart. PKD has been associated with many cardiac
abnormalities including the arrhythmogenic remodeling in clinical evaluations. In our
current study, we hypothesized that Pkd2 gene mutation results in structural and
functional defects in the myocardium. The structural and functional changes of Pkd2
mutant hearts were analyzed in the myocardial-specific Pkd2 knockout (KO) mouse.
We further assessed a potential role of TGF-b1 signaling in the pathology of Pkd2KO hearts. Hearts from age-matched 6-month-old MyH6•Pkd2wt/wt (control or wildtype) and MyH6•Pkd2flox/flox (mutant or Pkd2-KO) mice were used to study differential
heart structure and function. Cardiac histology was used to study structure, and
the “isolated working heart” system was adapted to mount and perfuse mouse
heart to measure different cardiac parameters. We found that macrophage1 (M1)
and macrophage 2 (M2) infiltration, transforming growth factor (TGF-b1 ) and TGFb1 receptor expressions were significantly higher in Pkd2-KO, compared to wild-type
hearts. The increase in the extracellular matrix in Pkd2-KO myocardium led to cardiac
hypertrophy, interstitial and conduction system fibrosis, causing cardiac dysfunction with
a predisposition to arrhythmia. Left ventricular (LV) expansion or compliance and LV filling
were impaired in fibrotic Pkd2-KO hearts, resulted in diastolic dysfunction. LV systolic
contractility and elastance decreased in fibrotic Pkd2-KO hearts, resulted in systolic
dysfunction. Compared to wild-type hearts, Pkd2-KO hearts were less responsive to
the pharmacological stress-test and changes in preload. In conclusion, Pkd2-KO mice
had systolic and diastolic dysfunction with arrhythmogenic hearts.
Keywords: polycystic kidney disease, cardiovascular, fibrosis, cardiac function, inflammation

INTRODUCTION
Autosomal dominant polycystic kidney disease (PKD) is the most common hereditary renal
disorder that affects 1 in 800 live births. Mutations in the Pkd1 and Pkd2 genes that encode
membrane-associated polycystin-1 and polycystin-2, respectively, contribute to the development
of cystic kidneys, which are characterized with severe renal fibrosis (1–3). Polycystin-1 is an
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the studies unless indicated. The MyH6•Pkd2 mutantwt/wt mice
were used as control or wild-type (WT), and MyH6•Pkd2
mutantflox/flox was designated as mutant (Pkd2-KO).

eleven-transmembrane protein interacting with polycystin-2, a
member of the transient receptor potential (TRP) protein family
that forms a calcium-permeable cation channel. Polycystin-2
is a non-selective cation channel with high calcium (Ca2+ )
permeability. The genetic mutation eventually causes kidney
enlargement, deformation, renal failure, and various extra-renal
manifestations (4–6).
Cardiovascular complications are a major cause of morbidity
and mortality in PKD patients. Cardiovascular manifestations in
PKD include hypertension (7, 8), left ventricular hypertrophy
(7, 9), valvular heart disease (10), intracranial and extracranial
aneurysms (11), and atrial fibrillation (11). Hypertension occurs
in 50–70% of patients before any significant depletion in the
glomerular filtration rate, and it occurs at an earlier age in PKD
patients compared to the general population (8). Hypertension
is a main early finding of PKD prior to any renal dysfunction,
which can accelerate end-stage kidney disease in about 60 percent
of PKD patients (12, 13).
The cardiovascular complications in PKD, including
hypertension and cardiac dysfunction, are thought to be
secondary to polycystic kidneys. However, recent studies indicate
that alterations in the polycystins expression directly affect
the cardiomyocyte, endothelial and vascular smooth muscles
functions, which could be responsible for cardiovascular disease
(14). Polycystin-1 and−2 have been proposed to function
as pressure sensors within the cardiovascular system (15).
Polycystin-1 and−2 function as mechanosensory proteins
in the cardiomyocytes to govern cardiomyocyte contractility
(16–18). Both polycystins play a role in intracellular calcium
homeostasis by interacting with the ryanodine receptor, which
induces calcium release from the endoplasmic reticulum in the
heart (19).
Left ventricular hypertrophy (LVH) is another cardiovascular
complication commonly measured in clinical studies using
echocardiography in PKD patients (9, 20). LVH is a significant
and independent risk factor for cardiovascular morbidity and
mortality, and it is associated with poor prognosis in PKD
patients. The presence of LVH affects clinical outcomes, with
increased risk of atrial or ventricular arrhythmia (21), systolic
and diastolic dysfunction (22, 23), congestive heart failure (24),
cardiovascular mortality (21), and sudden cardiac death (21).
LVH has a high prevalence in PKD patients with hypertension
(7) or even in non-hypertensive PKD patients (25). In extensive
echocardiographic analyses, LVH is predicted to be associated
with left ventricular fibrosis (9, 26). Cardiac fibrosis is a scarring
process in the cardiac muscle with collagen deposition, fibroblast
activation, and fibroblasts differentiation to myofibroblasts (27).
Our current studies examined the hypothesis that Pkd2 gene
mutation resulted in structural and functional heart defects. We
studied fibrosis and fibrotic pathways in the cardiac tissues of
Pkd2 mutant mouse model, and the effect of Pkd2 gene mutation
on cardiac function was studied using an isolated working
heart apparatus.

The Pkd2-KO Hearts Were Characterized
With Hypertrophy, Cardiac Fibrosis, and
Fibrotic Conduction System
The most apparent phenotype in the Pkd2-KO hearts was
hypertrophy and interstitial fibrosis. The Pkd2-KO left
ventricular (LV) myocardial thickness (Figures 1A,B) and
heart-to-body-weight ratio (Figure 1C) were significantly
increased in Pkd2-KO compared to control WT hearts. The
extensive diffuse and reactive interstitial fibrosis of LV were
significantly higher in Pkd2-KO, compared to WT hearts
(Figures 1D,E). The size of LV myocardiocytes was significantly
larger in Pkd2-KO than WT hearts (Figures 1F,G), supporting
the myocyte hypertrophy in Pkd2-KO hearts. The sinoatrial
node (SAN) and atrioventricular node (AVN) were also studied
to examine fibrosis in the cardiac conduction system in Pkd2-KO
mice. Upregulation of fatty and fibrotic tissues was observed in
SAN and surrounding tissues in Pkd2-KO mice (Figure 2A).
Although significant fibrosis was detected in SAN, fibrosis was
not statistically significant in AVN between Pkd2-KO and WT
hearts (Figure 2B). Because no significant fibrosis was found in
AVN, cell numbers were further analyzed (Figure 3). AVN was
identified by both its position within the heart and localization
of hyperpolarization-activated cyclic nucleotide-gated channel 4
(HCN4), which is known to localize in heart conduction systems.
AVN significantly had a lower cell number in Pkd2-KO than
WT hearts.
Because heart conduction systems including SAN and AVN
have an important role in electro-cardiac propagation (28, 29),
electrocardiac properties were further analyzed in Pkd2-KO
mice. The heart rate based on the in vivo electrocardiogram
(ECG) was 583 ± 5 beats per minute for the WT mice and
625 ± 10 beats per minute for Pkd2-KO mice; we did not
observe an apparent irregularity in ECG (Figure 4A). In order
to evaluate the electrical activity of the heart in the absence of
neurohumoral effects, we obtained an ex vivo ECG from isolated
hearts (Figure 4B). Without neurohumoral effects, WT hearts
showed a regular rhythm with 125 ± 20 beats per minute, and the
Pkd2-KO hearts had arrhythmic heart rate of 127 ± 22 beats per
minute evidence from atrial fibrillation or atrioventricular block
characterized by irregular R-R intervals. Cardiac arrhythmia was
also evidence in Pkd2-KO hearts at higher preloads.
Based on these analyses, our studies indicated that the Pkd2KO hearts were hypertrophied with interstitial fibrosis and
abnormal SAN and AVN. The impact of cardiac and conduction
system fibrosis might thus result in arrhythmogenic hearts in
Pkd2-KO mice.

The Pkd2-KO Hearts Had Abnormal
Systolic and Diastolic Functions

RESULTS

The heart-specific Pkd2 mutant knockout did not show any
behavior issue, at least not within the end-point of our
studies at 6-months of age. However, because these mice had
cardiac hypertrophy and fibrosis (Figure 1), heart functions were

To identify any abnormality in the structure and function of
PKD hearts, transgenic heart-specific mice were used throughout
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FIGURE 1 | The hearts from Pkd2-KO mice are characterized with hypertrophy and fibrosis. (A–C) Masson’s trichrome staining was used to analyzed hearts from
wild-type (WT) and Pkd2-KO (Pkd2) mice. Representative of left ventricular thickness (hypertrophy) is shown (A) and quantified (B,C). (D,E) Left ventricular (LV) fibrosis
is analyzed; arrows indicate fibrosis (D). LV fibrosis was quantified (E). Data show a significant increase in LV myocardial hypertrophy and fibrosis in Pkd2-KO
compared to WT mice. Fibrosis revealed by trichrome cooperation in the tissue was quantified with binary masking of the blue-color image (D,E). WGA staining was
used for cell surface staining and cell size measurement. Representative of LV cardiomyocyte size (hypertrophy) is shown (F) and quantified (G). N = 4 mice for each
WT and Pkd2-KO group at age matched of 6 months old. **p < 0.01; ***p < 0.001.

evaluated independently from the autonomic neuronal system
by analyzing the left ventricular pressure-volume relationship
(PV loop). PV loop allows a more precise analysis of heart
functions by plotting the changes in left ventricular pressure
and volume during each cardiac cycle. In order to quantify
the changes in heart functions during physiologic stresses, LV
parameters in both WT and Pkd2-KO were further evaluated
in response to adrenaline (4 µg/L) or diltiazem (0.08 µg/L;
Figure 5A). As expected, while adrenaline increased heart rate
and contractility via β1 -receptors, diltiazem had a negative
inotropic and negative chronotropic effects in both WT and
Pkd2-KO hearts (Supplementary Table 1). The end-systolic
pressure volume relationship (ESPVR) is a relationship between
LV pressure (LVP) and volume (LVV) at the end of the systole,
and the ESPVR is considered a marker for LV systolic contractile
function and elastance (30–32). Our results demonstrated that
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the LV ESPVR, stroke volume (SV), and ejection fraction (EF)
didn’t change significantly after adrenaline or diltiazem in Pkd2KO hearts (Figure 5B), which could be a result of decreased
heart muscle contractility due to fibrosis and systolic dysfunction
of LV. Despite no changes in the ESPVR, SV, and EF in Pkd2KO hearts, the cardiac output (CO) was significantly altered by
adrenaline or diltiazem. Importantly, the CO in responses to the
pharmacological agents was significantly less in Pkd2-KO than
WT hearts primarily due to contractility dysfunction in Pkd2KO hearts. The LV Pmax (maximum pressure) and LV ESP
(end-systolic pressure) were higher in Pkd2-KO hearts before
and after adrenaline and diltiazem, which could be due to LV
fibrosis, stiffness, structural changes, and narrow LV chamber
(Supplementary Table 1).
Preload is used to express EDV (end-diastolic volume);
therefore, the higher the preload is, the greater the EDV is.

3

November 2021 | Volume 8 | Article 772961

Amirrad et al.

Autosomal Dominant Polycystic Kidney Disease

FIGURE 2 | The sinoatrial node (SAN) Pkd2-KO mice are characterized with fibrosis and fatty infiltration. Masson’s trichrome staining was performed in wild-type (WT)
and Pkd2-KO (Pkd2) mouse hearts. (A) A significant increase of fibrotic tissue is seen in SAN of right atrium in PKD mouse compared to WT. Boxes indicated SAN,
and the left panel is further magnified and shown in the right panel. (B) No significant difference of fibrotic tissue is detected in AVN of right atrium in Pkd2-KO mouse.
Boxes indicated AVN, and the left panel is further magnified and shown in the right panel. AO, aorta; AVN, atrioventricular node; CFB, central fibrous body; CT, Crista
terminalis; ENC, endocardium; EPC, epicardium; FI, fatty infiltration; IVS, interventricular septum; LV, left ventricle; RA, right atrium; RV, right ventricle; SA, sinoatrial
node; SAA, sinoatrial artery. Scale Bar = 20 mm. N = 6–10 mice for each WT and Pkd2-KO group at age matched of 6 months old. ***p < 0.001.
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FIGURE 3 | Cell number is decreased in Pkd2-KO mouse atrioventricular node. (A) Heart tissues were stained with anti-HCN4 antibody used as a marker for the
myocardial conduction system (green staining). Atrioventricular node (AVN) is identified by both location and HCN4-postive staining indicated by the red circles; RV,
right ventricle. (B) The AVN is next identified as region of interest. (C) Number of cell nucleus (DAPI; blue staining) is counted. (D) Data reveal a significantly lower
number of cells in AVN of Pkd2-KO mouse hearts. N = 5 mice for each WT and Pkd2-KO group at age matched of 6 months old. **p < 0.01.
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FIGURE 5 | The cardiac function of Pkd2-KO mice is not responsive on
changes in cardiac stresses. (A) Individual graphs of the relationship between
left ventricle pressure (LVP) and left ventricle volume (LVV) heart function are
shown before and after injection of adrenaline (4 mg/L) and diltiazem (0.08
mg/L) in wild-type (WT) and Pkd2-KO (Pkd2) hearts. (B)
End-systolic-pressure-volume relationship (ESPVR, an index of systolic
contractility function), stroke volume, ejection fraction, and cardiac output are
used to evaluate the heart responses on positive-stress (adrenaline) and
negative-stress (diltiazem). N = 3–4 mice for each WT and Pkd2-KO
age-matched 6 months old. Statistical significance between control and
treatment is indicated with asterisk (*) sign; between genotypes in hash (#). *p
< 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 compared to control within
the same genotype. # p < 0.05; ### p < 0.001; #### p < 0.0001
compared to the corresponding WT.

FIGURE 4 | The hearts from Pkd2-KO mice with no autonomic input have
irregular beats. (A) Representatives of in vivo electrocardiogram (ECG) are
shown with averaged frequency of 540–600 beats/min in wild-type (WT) and
Pkd2-KO (Pkd2) mice. (B) Representatives of ex vivo ECG with no autonomic
input are shown with different preloads of 5, 10, and 15 mmHg. The Pkd2-KO
heart ECG shows irregular heartbeat with normal QRS shape. All ECG from
Pkd2-KO showed irregular R-R intervals (arrows). N = 3–4 mice for each WT
and Pkd2-KO age-matched 6 months old.

EDV depends on left ventricular compliance during diastole. The
5, 10, and 15 mmHg preload pressures were therefore used to
study EDV and other cardiac functions (Figure 6A). In Pkd2KO mice, the EDV decreased and did not change with increasing
preload due to abnormal LV expansion or compliance and filling
impairment in the fibrotic hearts (Supplementary Table 2).
Decreased EDV subsequently led to decrease in SV and CO
significantly in Pkd2-KO compared to WT hearts (Figure 6B).
Furthermore, dP/dtmin which is a valuable marker for diastolic
function (25) was significantly decreased in Pkd2-KO than WT
hearts, indicating Pkd2-KO hearts had a diastolic failure due
to compliance and filling impairment. Finally, the ESPVR was
significantly higher in Pkd2-KO than the WT hearts in all
preloads (Figure 6B). The steep and leftward of ESPVR slope was
most likely not due to the improved myocardial function, but it
was due to a narrow chamber in the hypertrophic and fibrotic LV.
In Pkd2-KO hearts, the EF could not compensate in response to
different preloads due to abnormal contractility in the fibrotic LV.

Frontiers in Cardiovascular Medicine | www.frontiersin.org

Higher preload did not affect ex vivo ECG in either rhythmic WT
or arrhythmic Pkd2-KO hearts. The ex vivo heart rate was also not
significantly altered by higher preloads in both mice (Figure 4B,
Supplementary Table 1).
The Pkd1 mutant myocytes have been previously shown to
have abnormal contractile calcium (16, 33). To investigate if it
was also the case in our Pkd2 mutant, we used lentivirus shRNA
knockdown system to examine the effects of Pkd2 knockdown
(KD) in contractility and calcium. The contractile efficacy in
myocytes was calculated by measuring the changes in muscle
displacement (cell shortening) for each myocyte beat. The
infection and blocking efficiencies of different Pkd2 shRNAs
were first verified in a kidney cell line and were further examined
in primary cultured myocytes (Supplementary Figure 1).
The Pkd2 shRNA-D was selected and used, because it
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and the ESPVR and SV among others were functionally
impaired in Pkd2-KO hearts (Figures 4–6). Together with the
arrhythmogenic characterization of Pkd2-KO hearts (Figure 4),
we speculated that interstitial and SAN fibrosis together with
hypertrophy and abnormal contractile calcium could play
important roles in Pkd2-KO hearts, leading to impaired cardiac
functions (Figures 1, 2).
To examine if/how fibrosis pathways were activated, TGFβ1 expression in the circulating plasma and heart itself was
analyzed with ELISA. While no difference was observed in
the plasma level of TGF-β1 , ELISA quantifications showed a
significant increase of TGF-β1 in Pkd2-KO compared to WT
hearts (Figure 7A). ELISA result was further supported by
the Western blot data, which showed a significant increase
in TGF-β1 expression level in Pkd2-KO compared to WT
hearts (Figure 7B). We subsequently evaluated TGF-β1 receptor
expression in the WT and Pkd2-KO hearts. The expression level
of TGF-β1 receptor was significantly higher in Pkd2-KO than
WT hearts (Figure 7C). To study the downstream effect of TGFβ1 , we also evaluated phosphorylated-Smad3 (pSmad3), totalSmad3 (tSmad3), and β-catenin expression levels in the hearts.
Our results showed higher expressions of pSmad3, tSmad3, and
β-catenin in WT compared to Pkd2-KO hearts (Figures 7D,E,
Supplementary Figure 4). While pSmad3 and tSmad3 were
higher in WT hearts, the fractionation study showed that pSmad3
and tSmad3 were localized in nuclear fraction of Pkd2-KO
myocytes (Supplementary Figure 5).
To confirm the Western blot data, immunohistochemistry
studies were performed to evaluate TGF-β1 and TGF-β1
receptor expressions. Consistent to our immunoblot results,
expressions of both TGF-β1 and TGF-β1 receptors were
significantly higher in Pkd2-KO compared to WT hearts
(Figures 8A,B). The expression levels of pSmad3 and βcatenin were also analyzed with immunofluorescence studies.
Consistent with our Western blot data, expressions of both
pSmad3 and β-catenin in cytosol were significantly lower
in Pkd2-KO compared to WT hearts (Figures 9A,B). The
nucleus-to-cytosol ratio of both pSmad3 and β-catenin were
significantly higher in Pkd2-KO than WT hearts, indicating
greater the nuclear localizations of pSmad3 and β-catenin in
Pkd2-KO hearts.
Because the Pkd2-KO hearts are characterized with a higher
TGF-β1 expression, we next analyzed a potential inflammation
in the Pkd2-KO hearts. We investigated potential infiltration
in heart tissues by macrophage M1 and M2, which is known
to be a local source for TGF-β1 (34). The immunofluorescence
analyses revealed that macrophage M1 and M2 infiltration was
significantly higher in the mouse Pkd2-KO compared to WT
hearts (Figures 10A,B).

FIGURE 6 | The cardiac function of Pkd2-KO mice is not responsive on
changes in preloads. (A) Individual graphs of pressure-volume loop show
effects of different preloads of 5, 10, and 15 mmHg on heart function. (B)
End-systolic-pressure-volume relationship (ESPVR, an index of systolic
contractility function), stroke volume, ejection fraction, and cardiac output are
used to measure heart functions in response to different pre-load levels. N
=3–4 mice for each WT and PKD age-matched 6 months old. Statistical
significance between control and treatment is indicated with asterisk (*) sign;
between genotypes in hash (#). *p < 0.05; ***p < 0.001; ****p < 0.0001; # p
< 0.05; ## p < 0.01; ### p < 0.001; #### p < 0.0001.

showed the highest knockdown efficiency. The myocyte
contractions and calcium oscillations in Pkd2 knockdown
myocytes occurred more frequently than in control myocytes
(Supplementary Figure 2;
Supplementary Videos 1, 2).
Further, the intracellular contractile calcium levels from
Pkd2-KD myocytes were significantly lower than those from the
control. The Pkd2-KD myocytes consistently and significantly
showed a decrease in contractility. We also confirmed the
knockdown studies in cardiomyocytes using a mouse model
with complete Pkd2 knockout (Supplementary Figure 3;
Supplementary Videos 3, 4).
Mouse
Pkd2
knockout
cardiomyocytes were characterized by increased contractile
oscillation frequency, decreased contractile calcium and
dampened contractile strength.

DISCUSSIONS

Fibrotic Pathways Were Activated in
Macrophage Infiltrated Pkd2 Mutant Hearts

Cardiovascular complications remain a major cause of mortality
and morbidity in patients with autosomal dominant polycystic
kidney disease (PKD) (21), but the etiopathogenesis behind
the complications is not completely understood. Our current

The contractile calcium and contractility were abnormal
in single Pkd2-KO myocytes (Supplementary Figures 2, 3),
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FIGURE 7 | The hearts from Pkd2-KO mice demonstrate abnormal fibrotic pathways. (A) ELISA measurements of TGF-β1 were done in circulating plasma (left panel)
and heart tissues (right panel). (B,C) Western blot analyses of mouse tissues show significantly higher expressions of TGF-β1 and TGF-β1 receptors in Pkd2-KO
(Pkd2) compared to WT mice. (D,E) Western blot analyses of mouse tissues show significantly higher expressions of tSMAD3, pSmad3, and β-catenin in WT
compared to Pkd2-KO mice. N = 4–6 mice for each WT and PKD age-matched 6 months old. *p < 0.05; **p < 0.01.

shown to involve in the process (36). The chemical loadinginduced fibrosis is usually associated with activation of
immune cells and inflammation, leading to the increased
extracellular matrix (36). Among the inflammatory cells,
the macrophages play the most extensive role in secreting
factors associated with inflammation. Our data showed that
the macrophage M1 and M2 significantly infiltrated Pkd2KO hearts. This suggested that M1 plays an essential role in
cardiac inflammation, and it might play a role in the onset
or progression of fibrosis in Pkd2-KO hearts (37). On the
other hand, M2 may involve in matrix deposition and tissue
remodeling in Pkd2-KO hearts (37). This suggested that
our Pkd2-KO hearts were still undergoing the inflammation
process and progressing toward fibrosis, although fibrosis
and remodeling could be detected and confirmed in
histochemistry analyses.

research focused mainly on the impact of Pkd2 gene mutation
on heart tissues and functions. Based on the structural changes in
the heart tissues, we showed clear evidence of cardiac remodeling,
including LV hypertrophy, and interstitial fibrosis. The Pkd2-KO
hearts showed a scarring process and cardiac muscle fibrosis with
the fatty fibrotic changes in the sinoatrial node (SAN), which
could serve as the underlying risk factor for cardiac arrhythmia
in PKD patients. This tissue remodeling was thus associated with
arrhythmogenic heart, systolic, and diastolic dysfunctions. Our
studies also pointed to the involvement of macrophages, secreting
anti-inflammatory TGF-β1 , and TGF-β1 receptor expression in
the Pkd2-KO heart tissues, and subsequently activating SMAD
and β-catenin pathways in Pkd2-KO hearts (Figure 11).
A common event in all myocardial fibrotic remodeling
involves either mechanical or chemical loading in the
heart (35), although fibroblast cilia have also been recently
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(Supplementary Tables 1, 2). An isolated working heart system
is commonly used to gather precise LV pressure-volume relations
(PV loop) independent of systemic neuronal effect. PV loop
is a powerful tool that provides us qualitative and quantitative
measurements of the heart functions. PV loop provides many
hemodynamic parameters that are not measurable by other
methods, including elastance, contractility, and stroke work.
The Pkd2-KO fibrotic hearts negatively affected expansion,
compliance, and filling of LV as indicated by the end-diastolic
volume (EDV). With less volume in the heart at the end of
diastole (EDV), the stroke volume (SV) and cardiac output (CO)
also decreased significantly. On the other hand, dP/dtmin , a
valuable marker for diastolic function, decreased in Pkd2-KO
hearts. Based on these results, Pkd2-KO hearts were further
confirmed to have diastolic failure due to compliance and filling
impairment. It is known that oxygen extraction during diastole
is higher than during systolic interval (43); perivascular fibrosis
can therefore restrict the oxygen diffusion during diastole, which
may further worsen diastolic function (43).
The end-systolic pressure-volume relationship (ESPVR) is
considered a marker for left ventricular contractility and
elastance (30–32). In Pkd2-KO hearts, the LV ESPVR did not
change significantly after adrenaline and diltiazem injection due
to fibrosis, decreased heart muscle contractility and systolic
dysfunction of the LV. This was also supported by the results
from the LV end-systolic volume (ESV), stroke volume (SV), and
ejection fraction (EF). Moreover, the ESPVR was also analyzed in
different preloads. The ESPVR with steep and leftward slope was
significantly higher in Pkd2-KO hearts in all preloads, indicating
a narrow chamber in the hypertrophic and fibrotic ventricle. In
addition, the contractile calcium was significantly lower, resulting
in weak contraction in Pkd2 mutant myocytes (18).
Fibrotic tissue forms a barrier between cardiomyocytes, which
can result not only in systolic dysfunction but also in electric
conduction impairment (43). Increased fibrosis within and
around SAN can cause structural destruction and dysfunction,
leading to arrhythmia (44, 45). While no apparent arrhythmia
was observed in the Pkd2-KO mouse model in vivo, the Pkd2KO hearts were susceptible to arrhythmia when hearts were
isolated away from neuronal input in the ex vivo studies. Atrial
fibrillation (AF) or AV block was seen in isolated Pkd2-KO hearts.
While the role of cardiac fibrosis is well-known in both atrial and
ventricular arrhythmias, SAN dysfunction is a common finding
in AF patients, particularly with advanced atrial fibrosis with
SAN involvement (44). We also looked at HCN4, an ion channel
responsible for the slow Na+ current in the heart conduction
system. HCN-positive nodal cells were significantly decreased in
the atria-ventricular node of Pkd2-KO hearts. Of note is that
HCN4 channels are required for generating slow current, which
is responsible for spontaneous depolarization of the specialized
myocytes of the heart pacemaker (46).
In conclusion, our studies indicated fibrosis in Pkd2-KO
hearts. Fibrosis in the conduction system might results in
arrhythmia, and thus the PKD patients might be susceptible to
atrial fibrillation (12) and potential arrhythmia-induced sudden
cardiac death (47). Our studies implicated that cardiac fibrosis
was also contributed to systolic and diastolic dysfunctions,

FIGURE 8 | The hearts from Pkd2-KO mice are characterized with upregulated
fibrotic pathways. (A,B) Immunohistochemistry staining demonstrated a
significant increase of TGF-β1 and TGF-β1 receptor (dark brown color) in
Pkd2-KO (Pkd2) hearts compared to the wild-type (WT). A total of 8
independent slides were used for each mouse. **p < 0.01; ****p < 0.0001.

The roles of mediators TGF-β1 , Smad, and β-catenin were
next examined because they are generally known signaling
pathways leading to cardiac fibrosis (35, 38–40). At least in the
Pkd2-KO mouse model, circulating TGF-β1 did not seem to
be increased, indicating that TGF-β1 might be restricted and
localized within cardiac tissues. Of note is that not only TGFβ1 but also its receptor had increased in expressions and might
have critical roles in the cardiac fibrosis. These studies were
supported by immunoblotting, ELISA, and immunohistology
studies. Both pSmad3 and β-catenin were significantly localized
in the nucleus of Pkd2-KO myocytes, indicating a significant
nuclear translocation and fibrotic signaling activation (38, 41).
Immunofluorescent studies and immunoblots in mouse tissues
indicated a lower total expression of pSmad3, tSMAD3, or βcatenin in Pkd2-KO hearts in cytosol. We further evaluated
tSMAD3 and pSMAD3 expressions in the nucleus. Results
indicated a higher nuclear localization of pSMAD3 in the Pkd2KO compared to WT hearts. Because of the low cytosolic
expression of pSmad3 or β-catenin in Pkd2-KO hearts, we further
speculated that this might be a compensatory mechanism by
the cardiac tissues to slow down the fibrotic process in Pkd2KO tissues.
Given a strong pathogenesis association between cardiac
fibrosis and myocardial dysfunction (42), we decided to
study the heart functions using the Pkd2-KO mouse model
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FIGURE 9 | The hearts from Pkd2-KO mice are characterized with a significant increase in nuclear localization of pSMAD3 and β-catenin. (A,B) Immunofluorescence
staining of pSmad3 (A) or β-catenin (B) revealed a significant increase in nuclear localization and nucleus to cytoplasm ratio of pSmad3 or β-catenin in Pkd2-KO
(Pkd2) compared to wild-type (WT) hearts. N = 4 mice for each group. A total of 8 independent slides were used for each mouse. *p < 0.05; **p < 0.01.

these mice were bred with heart-specific transgenic mice MyH6
(Jackson Laboratory; stock#011038). MyH6•Pkd2wt/wt mouse is
denoted as wild-type (WT; control), and MyH6•Pkdflox/flox is
designated as mutant or Pkd2-KO. Heart structure, function and
electrocardiogram (ECG) were examined and measured at 6months-old of age. Both male and female mice were used, and sex
was identified to be an independent covariate to heart functions.

which are seen in PKD patients (48). A potential prospect
for therapeutic manipulation might therefore involve cardiac
inflammation induced by TGF-b1.

MATERIALS AND METHODS
Throughout our studies, mice were used to examine the
structural and functional changes of the heart. Our animal studies
were approved by the Chapman University Institutional Animal
Care and Use Committee (IACUC# 2020-1132 and PHS# D1700960). The Pkd2flox/flox mice were previously given from Dr.
Jing Zhou’s laboratory at Harvard Medical School (49, 50);
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Masson’s Trichrome Staining
To evaluate myocadiac fibrosis and hypertrophy, heart tissues
were collected and fixed in 10% formalin. The tissues were
dehydrated in ethanol and xylene, embedded in liquid paraffin,
and cut with a thickness of 5 µm. Cut sections were stained with
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FIGURE 10 | The hearts from Pkd2-KO mice are significantly infiltrated by macrophages. (A,B) Immunofluorescence staining revealed a significant higher number of
macrophages M1 and M2. Image was quantified by binary masking of the red or green fluorescence image. N = 4 mice for each WT and Pkd2-KO age-matched 6
months old. *p < 0.05.

citrate buffer (10 mM sodium citrate, 0.05% tween-20, pH
6.0). Once boiled, slides were transferred from phosphatebuffered saline (PBS) to the sodium citrate buffer in pressure
cooker for 10 min, and then cooled to room temperature
for 30 min. To permeabilize the tissues, slides were washed
with permeabilization buffer containing 0.3% triton-100 in
PBS for 10 min. After permeabilization, slides were blocked
with 5% bovine serum albumin and 0.1% triton-100 in
PBS solution and subsequently processed to detect specific

Masson’s trichrome kit (Cat# 25088-1; Polysciences, Inc.), and
images were visualized and captured using KEYENCE BZ-X710
or Nikon Eclipse Ti microscope.

Immunofluorescence Studies
To examine protein localization and expression, the formalinfixed tissues were de-paraffinized. After deparaffinization
and dehydration of paraffin sections, heat-induced epitope
retrieval was performed using a pressure cooker and sodium
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FIGURE 11 | Hypothetical diagram summarizes the pathogeneses of PKD hearts. We hypothesize that hearts from Pkd2-KO mice are characterized by the
overexpression of TGF-β1 receptor. Local TGF-β1 secretion by infiltrating macrophages further exacerbates the activation of fibrotic pathways resulting in hypertrophy
and interstitial fibrosis. Subsequent activation of TGF-β1 receptor results in the activation of pSMAD3 and b-catenin in the myocytes. The fibrosis in the sinoatrial node
and surrounding tissue can results in arrhythmogenic heart. All of which will cause systolic and diastolic cardiac dysfunction.

for macrophages M1detection, anti-CD163 antibody (1:50; sc20066; Santa Cruz, Inc), and anti-CD-206 (1:100; Cat# ab91992;
Signaling, Inc) antibodies for macrophages M2 detection,
followed with horse anti-mouse antibody Texas Red (1:1,000;
Cat# NC9634446; Thermo Fisher Scientific), and AlexaFluor488 goat anti-rat fluorescence secondary antibody (1:500; Cat#
ab6840; Abcam, Inc), AlexaFluor-488 secondary goat anti-mouse
antibody (1:1,000; Cat# ab150113; Abcam, Inc), and AlexaFluor488 goat anti-rabbit fluorescence secondary antibody (1:500; Cat#
′
ab91992; Signaling, Inc). In all cases, we used 4 ,6-diamidino-2phenylindole (DAPI) as a nuclear binding dye. All images were
taken with the confocal A1R+ Nikon microscope (Version 4.30).

proteins. All washing steps were done three times with
PBS-T (tween-20, 0.05%).
For cell surface staining and cell size measurement, tissue
slides were incubated with wheat germ agglutinin (WGA)
(1:1,000; Cat# FL-1021; Vectorlabs) for 20 min. To detect
specialized conduction cells in the atrioventricular node, tissues
were incubated with rat anti-HCN4 antibody (1:1,000; Cat#
ab32675; Abcam, Inc.) overnight at 4◦ C in a humidified
chamber followed with AlexaFluor-488 goat anti-rat fluorescence
secondary antibody (1:500; Cat# ab6840; Abcam, Inc). To
study fibrotic pathways, anti-β-catenin (1:50; Cat# sc-133240;
Santa Cruz, Inc.) and anti-pSMAD3 (1:1,000; Cat# sc-517575;
Santa Cruz, Inc) antibodies were used in the same manner as
anti-HCN4 antibody followed with AlexaFluor-488 secondary
goat anti-mouse antibody (1:1,000; Cat# ab150113; Abcam,
Inc). To evaluate macrophages infiltration, tissues were stained
with anti-NOS2 antibody (1:50; Cat# sc-7271; Santa Cruz,
Inc), and anti-CD-86 (1:50; Cat# sc-52448; Santa Cruz, Inc)
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Immunohistology
To examine protein localization and expression, the formalinfixed tissues were de-paraffinized. After deparaffinization and
dehydration of paraffin sections, heat-induced epitope retrieval
was performed using a pressure cooker and sodium citrate buffer
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through Western blot analysis. The shRNA sequences used in our
experiments are shown below.

(10 mM sodium citrate, 0.05% tween-20, pH 6.0). Once boiled,
slides were transferred from PBS to the sodium citrate buffer
in pressure cooker for 10 min. Slides were then cooled to room
temperature for 30 min, and permeabilized with permeabilization
buffer containing 0.3% triton-100 in PBS for 10 min. To
block endogenous peroxidase activity, slides were incubated in
3% hydrogen peroxide for 10 min and blocked with animalfree blocking solution (Cat# 15019; Cell Signaling, Inc.). After
blocking, slides were incubated overnight at 4◦ C with mouse
monoclonal anti-TGF-β1 (1:50; Cat# sc-130348; Santa Cruz, Inc.)
or rabbit polyclonal anti-TGF-β1 receptor (1:100; Cat# ab235178;
Abcam, Inc.) and subsequently incubated with SignalStain Boost
Detection Reagent (HRP mouse; Cat# 8125; or HRP Rabbit; Cat#
8114; Cell Signaling, Inc.) for 30 min at room temperature. Slides
were then incubated for 2–10 min with SignalStain DAB (Cat#
8059; Cell Signaling, Inc.), immersed in distilled H2 O, stained
with hematoxylin (Cat# 14166; Cell Signaling, Inc.) and mounted
with coverslips. All washing steps were done three times with
PBS-T (tween-20, 0.05%).

Sequences

scrambled control

5 -TGA CCA CCC TGA CCT ACG GCG TGC AGT GC-3

′

′

Pkd2 A

5 -TTG TGC ATC TTG ACC TAC GGC ATG ATG AG-3

Pkd2 B

5 -TAC GGC ATG ATG AGC TCC AAT GTG TAC TA-3

′

′

′

′

′

′

Pkd2 C

5 -TTT GAT TTC TTC CTG GCA GCC TGT GAG AT-3

Pkd2 D

5 -GTC TGG ATT AAG CTC TTC AAA TTC ATC AA-3

′

′

Cytosolic Calcium Measurements
To observe cytosolic calcium in cultured cardiomyocytes, cells
were incubated with 10 µM fura-2AM (Invitrogen) and protected
from light for 30 min. Calcium was measured by comparing
fura-2 excitation at 340 nm (bound calcium) and 380 nm (free
calcium). After each experiment, free cytosolic calcium was
determined by perfusing ionomycin (10 µM final concentration)
to obtain the maximum calcium signal followed by the addition
of EGTA (2 mM final concentration) to observe the minimum
calcium signal. All experiments were performed at 37◦ C in a
heated microscope chamber.

Western Blot Analyses
To evaluate protein expressions, proteins were extracted from
the tissues using radioimmunoprecipitation assay (RIPA) lysis
buffer (Cat# 89901, Thermo Fisher, Inc.) containing Halt protease
inhibitor cocktail (Cat# 78425, Thermo Fisher, Inc.). Total
protein was quantified using the Bradford assay. Extracted
proteins (25–50 µg) were loaded into 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and
transferred onto nitrocellulose membrane afterward. For nuclear
fractionation, immunoprecipitation with anti-Histone H3 was
used and loaded to the gels. The membrane was then blocked
with 5% dry milk and subsequently processed to detect specific
proteins using a standard method.
We used the following primary antibodies: rabbit polyclonal
anti-TGF-β1 (1:1,000; Cat# ab92486; Abcam, Inc.), rabbit
polyclonal anti-TGF-β1 receptor (1:1,000; Cat# ab31013; Abcam,
Inc.), mouse monoclonal anti-β-catenin (1:100; Cat# sc-133240;
Santa Cruz, Inc.), rabbit monoclonal pSmad3 (1:1,000; Cat#
9520s; Cell Signaling, Inc.), rabbit monoclonal Smad3 (1:1,000;
Cat# 9523s; Cell Signaling, Inc.), rabbit polyclonal histone H3
(1:1,000; Cat# 9715s; Cell Signaling, Inc.), and anti-GAPDH
(1:100; Cat# sc-365062; Santa Cruz, Inc.). Except for antiGAPDH antibody which was already tagged with horseradish
peroxidase (HRP), HRP-tagged secondary antibodies were used
accordingly, followed with chemiluminescent substrate (Cat#
34577; Thermo Fisher Scientific, Inc.). Protein detection was
carried out with Bio-Rad imager (ChemiDocTM XRS+ System
with Image LabTM Software; Cat# 1708265; Bio-Rad, Inc.).

Enzyme-Linked Immunosorbent Assay
(ELISA)
To detect TGF-β1 in the circulating plasma, blood was collected
from a submandibular vein (cheek punch) using a heparinized
tube. Within 30 min of collection, blood was centrifuged for
15 min at 1000 × g at 4 ◦ C, and supernatant was collected for
the ELISA assay. To detect TGF-β1 in the heart, the heart tissues
were collected and homogenized in RIPA buffer containing Halt
protease inhibitor cocktail, and total protein was quantified with
Bradford assay from a commercially available kit (Cat# PI23227;
ThermoFisher Scientific, Inc.).
The TGF-β1 level was measured using a commercially
available mouse TGF-β1 ELISA kit (Cat# LS-F5184, LSBio, Inc.).
The assay was based on the sandwich ELISA method. Each
well had been pre-coated with TGF-β1 antibody. Tissue lysate
samples were added to the wells, and the target antigen (TGFβ1 ) was bound to the antibody. The unbounded proteins were
washed away, and biotin-conjugated detection antibody was
added, which bound to the captured antigen. Avidin-tagged HRP
′
′
conjugate was added to bind with biotin. The TMB (3,3 ,5,5 tetramethylbenzidine) detection substrate was added to react
with the HRP enzyme leading to color development, which was
proportional to total TGF-β1 bound. A stop solution (sulfuric
acid) was added to terminate the color development reaction, and
the optical density of each well was measured at a wavelength of
450 nm.

ShRNA Knockdown
Lentiviral vectors containing shRNA to Pkd2 knockdown
(Origene; pGFP-C-shLenti clone ID: TL310397) were transfected
into HEK293T cells. Viral supernatants were collected and pooled
at 24- and 48-h post-transfection. Primary mouse myocytes were
then incubated with pseudoviral particles and 8 µg/ml polybrene
for 48 h prior to analysis. Transduction efficiency was observed
via GFP reporter fluorescence, and Pkd2 knockdown was verified
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Descriptions

Electrocardiogram (ECG) and Heart
Functions
To study isolated heart functions, the 6-month-old mouse
was injected with heparin (100 units; IP) to prevent blood
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was also used for image capture, segmentation, 3D object
reconstruction, and automatic object recognition. A Photometric
Coolsnap EZ CCD Monochrome Digital Camera was used to
capture images with a 1392 × 1040 imaging array to resolve
fine details of the images. Binary masking was used to calculate
cell size, fibrosis, ventricular thickness, and image intensity for
protein expression and localization based on granularity, shape,
size, and pixel intensity. Quantitation of Western blots was done
with the NIH Fiji ImageJ (Version 2.1). After a box of the
intended proteins was drawn using the “gel” analysis function,
the area under the curve was measured for the intensity of
each protein band. All images were finalized on a six-core Mac
Pro, 3.9 GHz to facilitate complete data extraction. Scale bars
are provided in all figures and videos to indicate the actual
image size.
A list of heart functions was measured or calculated
using Emka Technology software. The software captured and
recorded real-time data for electrical heart propagation,
cardiac contractility, heart rate, left ventricle pressure
and volume, preload, afterload, aortic pressure, and
aortic outflow. These data were further used to calculate
stroke volume, cardiac output, end-diastolic/systolic
volume, and left atrial pressure rise and fall. Additional
analyses were performed in Microsoft Excel for macOS
(Version 16.48).
Our statistical analyses were performed using GraphPad
Prism for macOS (Version 9.1). To compare two groups of
unpaired datasets, a non-parametric student t-test was used with
two-tail assuming no Gaussian distribution. For comparison
within 3 or more groups with no matching datasets, we used
non-parametric or mixed ordinary one-way ANOVA. The mean
of each group was then compared with the mean of every
other group using Tukey post-hoc multiple comparison test with
multiplicity adjusted P-value for each comparison. P < 0.05 was
considered significant in our studies. A more precise P-value
was reported separately in the graphs. The total measurements
and N values were also reported independently in each
figure legend.

coagulation and anesthetized with ketamine 8–10 min later (200350 mg/kg; IP). Mouse’s chest was wiped clean with water,
dried, and shaved to obtain in vivo ECG. The ultrasonic gel was
warmed to 37◦ C to reduce stress to the mouse. The electrodes
were then placed onto the mouse’s chest. One electrode was
placed around the xiphoid process of the left side of (the)
sternum, and the other electrode at the 4th or 5th intercostal
space on the right side. The ECG reading was taken at 5s interval.
Immediately after obtaining in vivo ECG, an incision
was made in the mid-abdomen toward the diaphragm. The
diaphragm was opened, the thoracic cage was cut bilaterally,
and the heart was dissected out. Immediately after the
heart dissection, the aorta was cannulated and perfused with
Krebs-Ringer solution (125 mM NaCl, 2.5 mM KCl, 1.25 mM
NaH2PO4, 2 mM CaCl2, 1 mM MgCl2 , 25 mM NaHCO3 ,
and 25 mM glucose), which was continuously bubbled with
carbogen (95% O2 and 5% CO2 ) to reach a pH of 7.4
at 38.0◦ C.
The ex-vivo perfusion of the mouse’s heart was performed,
the left atrium was cannulated, and cardiac function
parameters were recorded using the working heart system
(Supplementary Video 5; Emka Technology, Inc.). This
approach provided quantitative measurements and heart
functions that other methods cannot measure, including
elastance, contractility, and stroke work. For evaluation of
cardiac electrical activity in the absence of neurohumoral
factors, an ex vivo ECG was obtained from the software
after placing ECG electrodes on the right atrium and
apex of the heart. Other cardiac parameters, including left
ventricle pressure (LVP), left atrial pressure (LAP), aortic
pressure (AP), and aortic flow (AoF) were obtained from the
software. The preload and afterload were adjusted manually
as needed.
The heart’s responses to the external stresses were examined
with a pharmacological stress test. The stress test was
performed by using epinephrine (4 µg/L) or diltiazem (0.08
µg/L). End-systolic pressure-volume relationship (ESPVR), left
ventricle pressure maximum (LVP max), and end-systolic
pressure (ESP), left ventricle end-systolic volume (LV ESV),
stroke volume (SV), and ejection fraction (EF) were obtained
from the software or pressure-volume analysis. In some
cases, preload was adjusted from 5 mmHg to either 10
or 15 mmHg. We used preload to indicate end-diastolic
volume (EDV); therefore, the higher the preload was, the
greater the EDV was. Preload was changed manually on
the preload reservoir graduated cylinder, located on the
isolated working heart system. After increasing the preload,
LV pressure max (LV Pmax), end-systolic pressure (ESP),
end-diastolic pressure (EDP), end-systolic volume (ESV), enddiastolic volume (EDV), stroke volume (SV), and ejection
fraction (EF) were obtained from the software data and pressurevolume analysis.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/Supplementary Materials, further inquiries can be
directed to the corresponding author.

ETHICS STATEMENT
The animal study was reviewed and approved by Chapman
University IACUC.

AUTHOR CONTRIBUTIONS
FA collected, analyzed data, drafted the manuscript, and
oversaw the experimental progress. RP bred mice and
served as a double-blind operator. KS assisted in tissue
processing, working heart system, and served as another
double-blind operator. BM performed calcium imaging

Data and Statistical Analysis
Image analyses were performed in Nikon NIS-Element for
Advanced Research software (Version 4.51). This software

Frontiers in Cardiovascular Medicine | www.frontiersin.org

14

November 2021 | Volume 8 | Article 772961

Amirrad et al.

Autosomal Dominant Polycystic Kidney Disease

Takahashi assisted FA, RP, and KS in reagent preparation and
chemical ordering at Chapman University.

studies. SN drafted the manuscript, designed research, and
oversaw the study. All authors were participating in finalizing
the manuscript.

SUPPLEMENTARY MATERIAL

FUNDING

The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fcvm.
2021.772961/full#supplementary-material

This work was supported in part by the NIH HL147311 and
AHA 19IPLOI34730020. Denisse Larin-Henriquez and Maki

REFERENCES

17. Criollo A, Altamirano F, Pedrozo Z, Schiattarella GG, Li DL, Rivera-Mejias
P, et al. Polycystin-2-dependent control of cardiomyocyte autophagy.
J Mol Cell Cardiol. (2018) 118:110–21. doi: 10.1016/j.yjmcc.2018.
03.002
18. Pedrozo Z, Criollo A, Battiprolu PK, Morales CR, Contreras-Ferrat A,
Fernandez C, et al. Polycystin-1 is a cardiomyocyte mechanosensor that
governs L-type Ca2+ channel protein stability. Circulation. (2015) 131:2131–
42. doi: 10.1161/CIRCULATIONAHA.114.013537
19. Anyatonwu GI, Estrada M, Tian X, Somlo S, Ehrlich BE. Regulation of
ryanodine receptor-dependent calcium signaling by polycystin-2. Proc Natl
Acad Sci USA. (2007) 104:6454–9. doi: 10.1073/pnas.0610324104
20. Morita H. Secondary cardiomyopathy in polycystic kidney disease syndrome.
Int Heart J. (2019) 60:10–11. doi: 10.1536/ihj.18-514
21. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in
autosomal dominant polycystic kidney disease. J Am Soc Nephrol. (1995)
5:2048–56. doi: 10.1681/ASN.V5122048
22. Kang YR, Ahn JH, Kim KH, Choi YM, Choi J, Park JR.
Multiple cardiovascular manifestations in a patient with autosomal
dominant polycystic kidney disease. J Cardiovasc Ultrasound. (2014)
22:144–7. doi: 10.4250/jcu.2014.22.3.144
23. Bardaji A, Vea AM, Gutierrez C, Ridao C, Richart C, Oliver JA. Left
ventricular mass and diastolic function in normotensive young adults with
autosomal dominant polycystic kidney disease. Am J Kidney Dis. (1998)
32:970–5. doi: 10.1016/S0272-6386(98)70071-X
24. de Chickera S, Akbari A, Levin A, Tang M, Brown P, Djurdev O, et
al. The risk of adverse events in patients with polycystic kidney disease
with advanced chronic kidney disease. Can J Kidney Health Dis. (2018)
5:2054358118774537. doi: 10.1177/2054358118774537
25. Schrier RW. Renal volume, renin-angiotensin-aldosterone system,
hypertension, and left ventricular hypertrophy in patients with
autosomal dominant polycystic kidney disease. J Am Soc Nephrol. (2009)
20:1888–93. doi: 10.1681/ASN.2008080882
26. Saito M, Okayama H, Yoshii T, Higashi H, Morioka H, Hiasa G, et
al. Clinical significance of global two-dimensional strain as a surrogate
parameter of myocardial fibrosis and cardiac events in patients with
hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. (2012)
13:617–23. doi: 10.1093/ejechocard/jer318
27. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac
fibrosis: the fibroblast awakens. Circ Res. (2016) 118:1021–
40. doi: 10.1161/CIRCRESAHA.115.306565
28. Bartos DC, Grandi E, Ripplinger CM. Ion channels in the heart. Compr
Physiol. (2015) 5:1423–64. doi: 10.1002/cphy.c140069
29. Moorman AF, de Jong F, Denyn MM, Lamers WH. Development
of the cardiac conduction system. Circ Res. (1998) 82:629–
44. doi: 10.1161/01.RES.82.6.629
30. Walley KR. Left ventricular function: time-varying elastance
and
left
ventricular
aortic
coupling.
Crit
Care.
(2016)
20:270. doi: 10.1186/s13054-016-1439-6
31. Aghajani E, Muller S, Kjorstad KE, Korvald C, Nordhaug D,
Revhaugand A, et al. The pressure-volume loop revisited: is the
search for a cardiac contractility index a futile cycle? Shock. (2006)
25:370–6. doi: 10.1097/01.shk.0000209521.20496.7a
32. Kass DA, Beyar R, Lankford E, Heard M, Maughan WL, Sagawa K. Influence
of contractile state on curvilinearity of in situ end-systolic pressure-volume
relations. Circulation. (1989) 79:167–78. doi: 10.1161/01.CIR.79.1.167

1. Zhang Y, Dai Y, Raman A, Daniel E, Metcalf J, Reif G, et al. Overexpression
of TGF-beta1 induces renal fibrosis and accelerates the decline in kidney
function in polycystic kidney disease. Am J Physiol Renal Physiol. (2020)
319:F1135–48. doi: 10.1152/ajprenal.00366.2020
2. Norman J. Fibrosis and progression of autosomal dominant polycystic
kidney disease (ADPKD). Biochim Biophys Acta. (2011) 1812:1327–
36. doi: 10.1016/j.bbadis.2011.06.012
3. Ratnam S, Nauli SM. Hypertension in autosomal dominant polycystic
kidney disease: a clinical and basic science perspective. Int J Nephrol Urol.
(2010) 2:294−308.
4. Menezes LF, Germino GG. The pathobiology of polycystic kidney
disease from a metabolic viewpoint. Nat Rev Nephrol. (2019)
15:735–49. doi: 10.1038/s41581-019-0183-y
5. Torres VE, Harris PC. Progress in the understanding of polycystic kidney
disease. Nat Rev Nephrol. (2019) 15:70–2. doi: 10.1038/s41581-018-0108-1
6. Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM,
Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. (2018)
4:50. doi: 10.1038/s41572-018-0047-y
7. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier
RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney
disease. J Am Soc Nephrol. (1997) 8:1292–7. doi: 10.1681/ASN.V881292
8. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC,
Duley IT, et al. Factors affecting the progression of renal disease in
autosomal-dominant polycystic kidney disease. Kidney Int. (1992) 41:1311–
9. doi: 10.1038/ki.1992.195
9. Suwa Y, Higo S, Nakamoto K, Sera F, Kunimatsu S, Masumura Y, et al. Old-Age
onset progressive cardiac contractile dysfunction in a patient with polycystic
kidney disease harboring a PKD1 frameshift mutation. Int Heart J. (2019)
60:220–5. doi: 10.1536/ihj.18-184
10. Leier CV, Baker PB, Kilman JW, Wooley CF. Cardiovascular abnormalities
associated with adult polycystic kidney disease. Ann Intern Med. (1984)
100:683–8. doi: 10.7326/0003-4819-100-5-683
11. Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in
autosomal dominant polycystic kidney disease. J Am Soc Nephrol. (2002)
13:269–76. doi: 10.1681/ASN.V131269
12. Yu TM, Chuang YW, Yu MC, Huang ST, Chou CY, Lin CL, et
al. New-onset atrial fibrillation is associated with polycystic kidney
disease: a nationwide population-based Cohort Study. Medicine. (2016)
95:e2623. doi: 10.1097/MD.0000000000002623
13. Romao EA, Moyses Neto M, Teixeira SR, Muglia VF, Vieira-Neto
OM, Dantas M. Renal and extrarenal manifestations of autosomal
dominant polycystic kidney disease. Braz J Med Biol Res. (2006) 39:533–
8. doi: 10.1590/S0100-879X2006000400014
14. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in
autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis.
(2010) 17:153–63. doi: 10.1053/j.ackd.2010.01.001
15. Sharif-Naeini R, Folgering JH, Bichet D, Duprat F, Lauritzen I, Arhatte M,
et al. Polycystin-1 and−2 dosage regulates pressure sensing. Cell. (2009)
139:587–96. doi: 10.1016/j.cell.2009.08.045
16. Altamirano F, Schiattarella GG, French KM, Kim SY, Engelberger F,
Kyrychenko S, et al. Polycystin-1 assembles with Kv channels to govern
cardiomyocyte repolarization and contractility. Circulation. (2019) 140:921–
36. doi: 10.1161/CIRCULATIONAHA.118.034731

Frontiers in Cardiovascular Medicine | www.frontiersin.org

15

November 2021 | Volume 8 | Article 772961

Amirrad et al.

Autosomal Dominant Polycystic Kidney Disease

45. Akoum N, McGann C, Vergara G, Badger T, Ranjan R,
Mahnkopf C, et al. Atrial fibrosis quantified using late gadolinium
enhancement MRI is associated with sinus node dysfunction
requiring pacemaker implant. J Cardiovasc Electrophysiol. (2012)
23:44–50. doi: 10.1111/j.1540-8167.2011.02140.x
46. DiFrancesco D. The role of the funny current in pacemaker activity.
Circ Res. (2010) 106:434–46. doi: 10.1161/CIRCRESAHA.109.20
8041
47. Yang B, Wang Q, Wang R, Xu T. Clinical manifestation, management
and prognosis of acute myocardial infarction in autosomal dominant
polycystic kidney disease. Kidney Blood Press Res. (2018) 43:1806–
12. doi: 10.1159/000495638
48. Huebener P, Abou-Khamis T, Zymek P, Bujak M, Ying X, Chatila
K, et al. CD44 is critically involved in infarct healing by regulating
the inflammatory and fibrotic response. J Immunol. (2008) 180:2625–
33. doi: 10.4049/jimmunol.180.4.2625
49. Pala R, Mohieldin AM, Sherpa RT, Kathem SH, Shamloo K, Luan
Z, et al. Ciliotherapy: remote control of primary cilia movement
and function by magnetic nanoparticles. ACS Nano. (2019)
13:3555–72. doi: 10.1021/acsnano.9b00033
50. Pala R, Mohieldin AM, Shamloo K, Sherpa RT, Kathem SH, Zhou
J, et al. Personalized nanotherapy by specifically targeting cell
organelles to improve vascular hypertension. Nano Lett. (2019)
19:904–14. doi: 10.1021/acs.nanolett.8b04138

33. Lee JJ, Cheng SJ, Huang CY, Chen CY, Feng L, Hwang DY, et al. Primary
cardiac manifestation of autosomal dominant polycystic kidney disease
revealed by patient induced pluripotent stem cell-derived cardiomyocytes.
EBioMedicine. (2019) 40:675–84. doi: 10.1016/j.ebiom.2019.01.011
34. Wang Y, Zhang L, Wu GR, Zhou Q, Yue H, Rao LZ, et al. MBD2 serves
as a viable target against pulmonary fibrosis by inhibiting macrophage M2
program. Sci Adv. (2021) 7:eabb6075. doi: 10.1126/sciadv.abb6075
35. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene
delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by
modulation of transforming growth factor-beta/Smad and p38 mitogenactivated protein kinase signaling pathways. Hum Gene Ther. (2009) 20:1190–
200. doi: 10.1089/hum.2008.204
36. Villalobos E, Criollo A, Schiattarella GG, Altamirano F, French KM,
May HI, et al. Fibroblast primary cilia are required for cardiac fibrosis.
Circulation. (2019) 139:2342–57. doi: 10.1161/CIRCULATIONAHA.117.
028752
37. Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization
in inflammation during infectious diseases. Int J Mol Sci. (2018) 19:1801.
doi: 10.3390/ijms19061801
38. Xiang FL, Fang M, Yutzey KE. Loss of beta-catenin in resident cardiac
fibroblasts attenuates fibrosis induced by pressure overload in mice. Nat
Commun. (2017) 8:712. doi: 10.1038/s41467-017-00840-w
39. Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, et al. Macrophage-stimulated
cardiac fibroblast production of IL-6 is essential for TGF beta/Smad
activation and cardiac fibrosis induced by angiotensin II PLoS ONE. (2012)
7:e35144. doi: 10.1371/journal.pone.0035144
40. Attaran S, Sherwood R, Dastidar MG, El-Gamel A. Identification of low
circulatory transforming growth factor beta-1 in patients with degenerative
heart valve disease. Interact Cardiovasc Thorac Surg. (2010) 11:791–
3. doi: 10.1510/icvts.2010.244384
41. Venkatesan N, Pini L, Ludwig MS. Changes in Smad expression
and subcellular localization in bleomycin-induced pulmonary
fibrosis. Am J Physiol Lung Cell Mol Physiol. (2004) 287:L1342–
7. doi: 10.1152/ajplung.00035.2004
42. Webber M, Jackson SP, Moon JC, Captur G. Myocardial
fibrosis in heart failure: anti-fibrotic therapies and the role of
cardiovascular magnetic resonance in drug trials. Cardiol Ther. (2020)
9:363–76. doi: 10.1007/s40119-020-00199-y
43. Piek A, de Boer RA, Sillje HH. The fibrosis-cell death axis in heart failure.
Heart Fail Rev. (2016) 21:199–211. doi: 10.1007/s10741-016-9536-9
44. Csepe TA, Kalyanasundaram A, Hansen BJ, Zhao J, Fedorov VV. Fibrosis:
a structural modulator of sinoatrial node physiology and dysfunction. Front
Physiol. (2015) 6:37. doi: 10.3389/fphys.2015.00037

Frontiers in Cardiovascular Medicine | www.frontiersin.org

Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Amirrad, Pala, Shamloo, Muntean and Nauli. This is an openaccess article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.

16

November 2021 | Volume 8 | Article 772961

